Slinda 28 Tab

INDICATIONS Oral hormonal contraception. PHARMACOLOGICAL CHARACTERISTICS Pharmacodynamics, SLINDA 's contraceptive action is based on different factors, the most important being ovulation inhibition The pharmacokinetics of SLINDA? after a single and repeated dose has been studied in comparison with the marketed product containing 3 mg of micronized Drospirenone in combination with with elinylestradiol. After administration of multiple doses, bioavailability relative to LINDA? was 76.51% for the AUCL These findings indicate that the total exposure to Drospitenone is lower for SLINDAS than for the combined product that is marketed in a 28-day cycle. CONTRAINDICATIONS * Hypersensitivity to the active paciplo or to the excipients contained in the coated tablets. + Deep vein thrombosis, current or previous pulmonary embolism. * Vascular diseases that occur with arterial thrombosis such as cerebrovascular accident, acute myocardial infarction, stable chronic angina, peripheral arterial disease, among others. Both as current disease or history of occurrence. Presence of a severe risk factor or several risk factors for arterial thrombosis such as: - Diabetes mellitus with vascular complication. - Severe hypertension. - Severe dysipoproteinemia. - Hereditary or acquired precision for venous or arterial thrombosis, as they resist- cia to PCA (protein-C activated) protein-C antithrombin Il deficiency, protein: S, hyperhomocysteinemia and antilostolpidic antibodies (anticardiolipin. lupus anticoagulant) Serious existing or previous liver disease, until the values ​​of the liver funcation "Adrenal insufficiency “Severe chronic kidney failure or acute kidney failure. “Existing or previous benign or malignant liver tumors. Known or suspected malignant pathologies of the genital organs or glands. breast, s are influenced by sex hormones. Rare vaginal bleeding of undiagnosed origin. Migraine with local neurological symptoms in the anamnesis.